GeoVax Labs, Inc. (NASDAQ:GOVX) Receives $14.20 Average PT from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has been given a consensus recommendation of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $14.20.

A number of brokerages have recently issued reports on GOVX. Alliance Global Partners began coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock. D. Boral Capital reiterated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a report on Friday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a report on Friday, November 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new position in GeoVax Labs during the 4th quarter worth $29,000. Virtu Financial LLC purchased a new position in GeoVax Labs during the 3rd quarter worth $97,000. Citadel Advisors LLC purchased a new position in GeoVax Labs during the 4th quarter worth $104,000. Finally, Geode Capital Management LLC grew its stake in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after buying an additional 33,440 shares during the last quarter. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Trading Down 3.9 %

Shares of NASDAQ:GOVX opened at $1.47 on Wednesday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The business’s fifty day simple moving average is $2.05 and its 200-day simple moving average is $2.66.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.